CytomX slumps ~15% amid FY22 miss, AbbVie pulls plug on CX-2029 studies

Tuesday, 28 March 2023, 17:39:52
CytomX Therapeutics (CTMX) stock fell ~15% on Tuesday after FY22 results missed estimates and the company said that AbbVie (ABBV) will not advance cancer drug CX-2029 into…
— Seeking Alpha

AbbVie Walks Away From CytomX Partnership, But Garnering Attention Of Big Pharma Partners

Tuesday, 28 March 2023, 17:35:14
CytomX Therapeutics Inc (NASDAQ: CTMX ) will weigh its options for CX-2029, a CD71-directed antibody-drug conjugate, after AbbVie Inc (NYSE: ABBV ) decided not to advance the drug into additional studies . CytomX and AbbVie have also concluded their research activities under a 2016 Discovery License and Collaboration Agreement. AbbVie paid $30 million upfront in 2016 to ink the deal and another $15 million in milestones in 2017 for the start of toxicology … Full story available on Benzinga.com
— Benzinga

Who Are Pfizer”s (PFE) Main Competitors?

Saturday, 25 March 2023, 18:38:05
Pfizer”s biggest competitors in the global pharmaceutical industry are Johnson & Johnson, Roche, Eli Lilly, AbbVie, Novo Nordisk, and Merck.
— Investopedia

Better Buy: AbbVie vs. Johnson & Johnson

Saturday, 25 March 2023, 10:30:00
These pharma giants beat the bear market last year.
— The Motley Fool

Eli Lilly Poised to Nab First to Market Advantage with its IL-23 Inhibitor Mirikizumab in Ulcerative Colitis, Creating an Opportunity to Build a Loyal Base Ahead of AbbVie and Janssen”s Respective IL-23 Entries, According to Spherix Global Insights

Saturday, 25 March 2023, 00:00:00

— Kwhen Finance